Results 1 to 10 of about 2,929 (206)

Efficacy of vonoprazan against bleeding from endoscopic submucosal dissection-induced gastric ulcers under antithrombotic medication: A cross-design synthesis of randomized and observational studies. [PDF]

PLoS ONE, 2021
Vonoprazan, a potassium-competitive acid blocker, is expected to be superior to proton pump inhibitors (PPIs) in preventing post-endoscopic submucosal dissection (ESD)-induced gastric bleeding.
Yu Hidaka, Toru Imai, Tomoki Inaba, Tomo Kagawa, Katsuhiro Omae, Shiro Tanaka   +5 more
doaj   +2 more sources

Vonoprazan - a new drug for inhibiting gastric acid secretion [PDF]

Journal of Education, Health and Sport, 2022
Introduction and purpose  Vonoprazan is a potassium-competent acid blocker (P-CAB). It has the potential to be an alternative to proton pump inhibitors (PPIs) as it inhibits hydrochloric acid secretion. The mechanism of action is different than PPIs -
Kacper Niewęgłowski, Natalia Wilczek, Michał Rycharski, Julita Niewęgłowska   +3 more
doaj   +3 more sources

Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Current Therapeutic Research, 2016
Background: For many patients, current treatments do not adequately resolve heartburn in nonerosive reflux disease (NERD). Objective: To compare vonoprazan and placebo with respect to the frequency and severity of heartburn in patients with NERD. Methods:
Yoshikazu Kinoshita, Katsuhiko Iwakiri
exaly   +3 more sources

Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism [PDF]

Scientific Reports
Our study investigates the effect of vonoprazan on albuminuria in diabetic kidney disease (DKD) patients compared to lansoprazole through a randomized controlled trial. Participants were randomized to receive either lansoprazole 30 mg or vonoprazan 20 mg.
Rabab Mahmoud Ahmed, Amin Roshdy Soliman, AbdelAal Mohammed   +2 more
doaj   +2 more sources

Awareness, attitudes, and clinical utilization of vonoprazan for Helicobacter pylori infection and gastroesophageal reflux disease among Chinese physicians: a nationwide cross-sectional study [PDF]

BMC Gastroenterology
Background Vonoprazan has been introduced as an alternative to proton pump inhibitors (PPIs) for Helicobacter pylori (H. pylori) infection and gastroesophageal reflux disease (GERD). Despite regulatory approval and guideline inclusion in China, physician
Hui Xu, Hao Zhao, Heqing Tao, Ligang Liu
doaj   +2 more sources

Dose and duration shape the efficacy of vonoprazan versus lansoprazole for erosive esophagitis: insights from meta-regression [PDF]

Therapeutic Advances in Gastroenterology
Background: Proton pump inhibitors (PPIs) are the standard treatment for erosive esophagitis (EE), yet 20%–40% of patients show inadequate response.
Po-Feng Huang, Hsuan-Wei Chen, Yao-Jen Liang   +2 more
doaj   +2 more sources

Vonoprazan versus Conventional Proton Pump Inhibitors Based Regimens in Helicobacter Pylori Eradication Therapy [PDF]

International Journal of Medical Arts, 2023
Background: Helicobacter pylori [H. Pylori] infection is a major risk factor for the development of gastric cancer. Gastric cancer witnessed a significant increase in recent decades. Thus, eradication of H.
Mohamed Ahmed, Waleed Mossa, Amr Rezk, Nasser kamal Elhamshary   +3 more
doaj   +1 more source

Evaluation of commonly used cardiovascular drugs in inhibiting vonoprazan metabolism in vitro and in vivo

Frontiers in Pharmacology, 2022
As a novel acid-suppressing drug, vonoprazan shows the potential to replace traditional proton-pump inhibitors. With its widespread use, some adverse effects that require further study have emerged due to drug–drug interactions.
Yiran Wang, Yiran Wang, Jihua Shi, Dapeng Dai, Jianping Cai, Shuanghu Wang, Yun Hong, Shan Zhou, Fangling Zhao, Fangling Zhao, Quan Zhou, Peiwu Geng, Yunfang Zhou, Xue Xu, Qingfeng Luo   +14 more
doaj   +1 more source

Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo

Pharmaceutical Biology, 2023
Context Poziotinib and vonoprazan are two drugs mainly metabolized by CYP3A4. However, the drug-drug interaction between them is unknown.Objective To study the interaction mechanism and pharmacokinetics of poziotinib on vonoprazan.Materials and methods ...
Shan Zhou, Fang-Ling Zhao, Shuang-Hu Wang, Yi-Ran Wang, Yun Hong, Quan Zhou, Pei-Wu Geng, Qing-Feng Luo, Jian-Ping Cai, Da-Peng Dai   +9 more
doaj   +1 more source

Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia [PDF]

, 2021
Backgrounds: Compared to proton pump inhibitors, vonoprazan exerts a greater inhibitory effect on gastric acid secretion and is useful for treating acid-related diseases, such as gastro-esophageal reflux disease.
12417, 12418, 12419, 12420, 12421, 12422, 12423, 12424, 12425, 12426, 12427, 12428, Furuta, Takahisa, Hamaya, Yasushi, Higuchi, Tomohiro, Iwaizumi, Moriya, Kagami, Takuma, Miyajima, Hiroaki, Osawa, Satoshi, Sugimoto, Ken, Suzuki, Takahiro, Tani, Shinya, Uotani, Takahiro, Yamade, Mihoko   +23 more
core   +1 more source